A novel rutin-fucoidan complex based phytotherapy for cervical cancer through achieving enhanced bioavailability and cancer cell apoptosis - 09/12/18
pages | 15 |
Iconographies | 11 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Rutin-Fucoidan (Ru-Fu), a new flavonoid-polysaccharide complex was prepared. |
• | The Ru-Fu complex was characterized by UV–vis, FT-IR, fluorescence spectrometer and DLS analysis and evaluated for in vitro anti-cancer activities. |
• | The drug release behavior at different pH (5.5, 6.8 and 7.4) shows that the sustained release of Ru from complex occurs preferentially at the desired endosomal pH (5.5). |
• | Ru-Fu complex is biocompatible to normal cells as well as human RBCs. |
• | Ru-Fu complex effectively involved in anti-proliferation, S-phase cell cycle arrest and apoptosis related cell death induction in HeLa cells. |
Abstract |
Recent studies on flavonoids forming complexes with macromolecules attract researchers due to their enhanced bioavailability as well as chemo-preventive efficacy. In this study, a flavonoid rutin (Ru) is non-covalently complexed with fucoidan (Fu) using the functional groups to obtain a therapeutic polymeric complex overcoming the limitations of bioavailability of rutin. The prepared novel rutin-fucoidan (Ru-Fu) complex is characterized for spectroscopic features, particle size and distribution analysis by DLS. It is shown that the complex displayed the nanostructural features that are different from that of the usual rutin-fucoidan mixture. The studies on drug release profiles at different pH (5.5, 6.8 and 7.4) show that the sustained release of compounds from complex occurs preferentially at the desired endosomal pH (5.5). Further, the chemopreventive potential of Ru-Fu complex is investigated against HeLa cells by cellular apoptotic assays and flow cytometric analysis. It showed that the complex is able to disrupt cell cycle regulation and has the ability to induce cellular apoptosis via nuclear fragmentation, ROS generation and mitochondrial potential loss. In vitro cell viability assay with Ru-Fu complex shows that the complex is biocompatible on normal cells. The hemolysis assay also reveals that the complex does not release hemoglobin from human red blood cells (RBCs). Thus, the study is envisaged to open up interests for developing such formulations against cervical cancer and other cancers.
Le texte complet de cet article est disponible en PDF.Abbreviations : Ru-Fu, HaCaT, HeLa, MTT, DMEM, FBS, LDH, AO, EtBr, DCFH-DA, Rh-123, Δψm, DAPI, FITC, PI, DMSO, PBS, MFI, IC, ROS, OD, CI, kDa, A
Keywords : Rutin-Fucoidan (Ru-Fu), HeLa cells, Cytotoxicity, Apoptosis, Cell cycle arrest, Hemolysis
Plan
Vol 109
P. 1181-1195 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?